Evidence map›Paper›PMID 40260937›Full record

ArticleProtein science : a publication of the Protein Society2025

Structural insights into the interaction between testis-specific Y-encoded-like protein 5 and ubiquitin-specific protease 7.

Marine Ancia, Khadija Wahni, Joudy Chakrowf, Asia El Aakchioui, Eloïse Claude, Guillaume de Lhoneux, Maxime Liberelle, Steven Janvier, Ekaterina Baranova, Julia Malo Pueyo and 7 more

Abstract read
In one paragraph

Article in Protein science : a publication of the Protein Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Marine AnciaMedicinal Chemistry Research Group, Louvain Drug Research Institute, Université catholique de Louvain, Brussels, Belgium.
Khadija WahniVIB-VUB Center for Structural Biology, Vlaams Instituut Voor Biotechnologie, Brussels, Belgium.
Joudy ChakrowfMedicinal Chemistry Research Group, Louvain Drug Research Institute, Université catholique de Louvain, Brussels, Belgium.
Asia El AakchiouiMedicinal Chemistry Research Group, Louvain Drug Research Institute, Université catholique de Louvain, Brussels, Belgium.
Eloïse ClaudeGenetic and Epigenetic Alterations of Genomes, de Duve Institute, Faculty of Pharmacy and Biomedical Sciences, Université catholique de Louvain, Brussels, Belgium.
Guillaume de LhoneuxGenetic and Epigenetic Alterations of Genomes, de Duve Institute, Faculty of Pharmacy and Biomedical Sciences, Université catholique de Louvain, Brussels, Belgium.
Maxime LiberelleMedicinal Chemistry Research Group, Louvain Drug Research Institute, Université catholique de Louvain, Brussels, Belgium.
Steven JanvierVIB-VUB Center for Structural Biology, Vlaams Instituut Voor Biotechnologie, Brussels, Belgium.
Ekaterina BaranovaVIB-VUB Center for Structural Biology, Vlaams Instituut Voor Biotechnologie, Brussels, Belgium.
Julia Malo PueyoVIB-VUB Center for Structural Biology, Vlaams Instituut Voor Biotechnologie, Brussels, Belgium.
Ariana Jijon VergaraMedicinal Chemistry Research Group, Louvain Drug Research Institute, Université catholique de Louvain, Brussels, Belgium.
Nicolas Papadopoulosde Duve Institute, Université catholique de Louvain, Brussels, Belgium.
Clémence Baltyde Duve Institute, Université catholique de Louvain, Brussels, Belgium.
Jérôme DejeuUniversité Marie et Louis Pasteur, SUPMICROTECH, CNRS, Institut FEMTO-ST, Besançon, France.
Anabelle DecottigniesGenetic and Epigenetic Alterations of Genomes, de Duve Institute, Faculty of Pharmacy and Biomedical Sciences, Université catholique de Louvain, Brussels, Belgium.
Joris MessensVIB-VUB Center for Structural Biology, Vlaams Instituut Voor Biotechnologie, Brussels, Belgium.
Raphaël FrédérickMedicinal Chemistry Research Group, Louvain Drug Research Institute, Université catholique de Louvain, Brussels, Belgium.ORCID 0000-0001-8119-1272

Funding

Fonds De La Recherche Scientifique - FNRS FNRS-EQP 31288018Fonds Wetenschappelijk Onderzoek 1193524NResearch Foundation-Flanders- Fonds de la Recherche Scientifique 30829584Stichting Tegen Kanker FAF-F/2018/1208VIB
6 · The paper itself

Abstract

The Alternative Lengthening of Telomeres (ALT) mechanism enables telomere maintenance, contributing to the immortality of certain cancer cells. Disrupting the interaction between testis-specific Y-encoded-like protein 5 (TSPYL5) and ubiquitin-specific protease 7 (USP7) has emerged as a promising strategy to target ALT-dependent cancers. While the N-terminal MATH domain of USP7 mediates the protein interaction, the regions of TSPYL5 involved in binding remain unclear. Here, we present a structural analysis of the TSPYL5-USP7 interaction to guide targeted therapeutic strategies. We showed that TSPYL5 is intrinsically disordered, with an unfolded N-terminal region and partial structure in the C-terminal half. In vitro, recombinantly expressed TSPYL5 binds USP7 with nanomolar affinity and is prone to C-terminal truncation. However, the truncated form retained a similar binding affinity for USP7, suggesting the primary interaction site resides in the N-terminal region of TSPYL5. We identified three key binding hotspots within TSPYL5: residues 65-97, residues 210-262, and residues 368-388. Moreover, TSPYL5 forms trimers that further assemble into hexamers. This study provides the first structural and quantitative analysis of the TSPYL5-USP7 interaction, highlighting these three binding sites. These findings lay the groundwork for the development of novel inhibitors targeting ALT-dependent cancers.

Indexed as

Ubiquitin-Specific Peptidase 7HumansModels, MolecularProtein BindingUbiquitin-Specific Peptidase 7USP7 protein, humanAlphaFoldALT mechanismbiolayer interferometrycancerco‐immunoprecipitationelectron microscopyhydrogen‐deuterium exchange mass spectrometrymass photometrymicroscale thermophoresispeptides screening

Identifiers

PMID40260937
PMCPMC12012732

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.